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■ SHORT COMMUNICATION ■
Introduction
Tamoxifen, a nonsteroidal antiestrogen, is one of the
standard adjuvant medications for breast cancer [1].
Because of its estrogenic agonistic effect on the uterus,
attention must be paid to the regular surveillance of 
the uterus during tamoxifen treatment, especially to the
condition of the endometrium [2–8]. Previous studies
have reported the changing histopathologic character-
istics of uterine leiomyoma on hysterectomy specimens
from postmenopausal breast cancer patients who 
received tamoxifen for at least 5 months. They noted
that cystic and edematous changes in the leiomyoma
were common findings, but none have found increased
mitotic figures in the leiomyoma [7,9]. In this article, we
present a case of mitotically active leiomyoma of the
uterus complicated with postmenopausal vaginal bleed-
ing in a breast cancer patient who had been taken tamo-
xifen for 2 years.
Case Report
A 56-year-old, gravida 4, para 3, abortus 1, breast
cancer patient was referred to our department because
of abnormal postmenopausal vaginal spotting for 
3 months.
Tracing back her history, she had uneventful men-
struation since menarche and experienced menopause
6 years previously. She did not take any hormone 
replacement therapy. Breast cancer was diagnosed 2
years previously, and conservative breast surgery was
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SUMMARY
Objective: Mitotically active leiomyoma of the uterus complicated with postmenopausal vaginal bleeding has
never been reported in Taiwan. Here, we present a case of mitotically active leiomyoma of the uterus complicated
with postmenopausal vaginal bleeding in a breast cancer patient who had been receiving tamoxifen for 2 years.
Case Report: A 56-year-old woman visited our clinic due to abnormal vaginal spotting for 3 months. This
patient had been menopausal for about 6 years without hormone replacement therapy. She had been suffering
from breast cancer, had undergone conservative breast surgery, and had been taking tamoxifen (20 mg/day) for
2 years. Pelvic ultrasound was performed and revealed an 8.97.7 cm uterine mass. After simple total hyster-
ectomy, we found an enlarged uterus with a mass over the posterior wall. Final pathology demonstrated a
mitotically active leiomyoma, adenomyosis of the uterus, and proliferation of the endometrium.
Conclusion: Endometrial cancer is rarely noted in breast cancer patients taking tamoxifen. Further, none have
reported mitotically active leiomyoma of the uterus. From this case, endometrial proliferation and mitotically
active leiomyoma of the uterus may be related to tamoxifen therapy, and should not be neglected in breast 
cancer patients. [Taiwanese J Obstet Gynecol 2006;45(2):167–169]
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undertaken. After the operation, she took tamoxifen
(20 mg/day) for 2 years. However, abnormal vaginal
spotting was noted 3 months ago. A series of gyneco-
logic examinations were performed to investigate the
cause of abnormal vaginal bleeding. The results were
as follows: cervical cytology was normal, endometrial
sampling revealed atypical glandular cells, and pelvic
ultrasound showed an 8.97.7 cm homogeneous
hypoechoic uterine mass over the posterior wall. There-
fore, under the impression of postmenopausal vaginal
bleeding with suspected uterine leiomyoma, total
abdominal hysterectomy with bilateral salpingo-
oophorectomy were performed. Final pathology reported
a round mass, 6.5 cm in diameter, in the myometrium,
which showed increased cellularity without coagulative
necrosis and atypia. The mitotic figures were counted 
up to 12 over 10 high-power fields. Mitotically active
leiomyoma was diagnosed (Figures 1 and 2). The other
portions of the specimen revealed chronic cervicitis,
endometrium of proliferative phase (Figures 3 and 4),
adenomyosis and normal ovaries and fallopian tubes.
Discussion
Tamoxifen, a nonsteroidal antiestrogen, is a derivative
of triphenylethylene. Initially, it was developed in 1967
for the study of prevention of implantation. Nowadays,
tamoxifen is the standard adjuvant therapy for post-
menopausal breast cancer women with positive estrogen
receptor protein [1–3]. Because of its estrogenic agonis-
tic effect on the uterus [3], recent studies have focused
on the relationship between tamoxifen and the patholo-
gic changes in the uterus, especially the endometrium.
The most common pathologic characteristic of the
endometrium after tamoxifen exposure is endometrial
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Figure 2. Mitotic figures (arrow) are increased and dis-
cerned in high-power field, which indicated the mitotically
active leiomyoma of the uterus (400, H&E).
Figure 1. Spindle-shaped tumor cells with elongated nuclei
and eosinophilic cytoplasm are arranged in fascicles, a char-
acteristic of leiomyoma (40, H&E).
Figure 3. The endometrium is in a proliferative phase with
cystic changes (40, H&E).
Figure 4. The endometrial gland, with pseudostratification
and a mitotic figure, indicates proliferative activity (400,
H&E).
polyp [6], which has an incidence of 8–36% [4]. The 
risk of endometrial cancer is about 3–10.7% and is rela-
ted to prolonged exposure to tamoxifen [4,5], especially
> 5 years [2,8].
Transvaginal ultrasonography may be beneficial for
the surveillance of the uterus and endometrium of
women on long-term tamoxifen therapy, the cutoff
point of the endometrial thickness was reported to be
5 mm. Endometrial cystic atrophy is the most common
pathologic finding in endometrium in patients receiv-
ing endometrial curettage or hysteroscopy, as endome-
trial thickness exceeds 5 mm examined by transvaginal
ultrasonography [6]. No ultrasonographic changes can
be detected before surgery. The echogenicity detected
from ultrasound for this patient revealed the same as
benign uterine leiomyoma.
According to the definition, uterine leiomyoma,
with 5 mitotic figures (MF) per 10 high-power fields
(HPF) without cellular atypia and coagulative tumor
cell necrosis, is named “mitotically active leiomyoma”
[10,11]. The number of mitotic figures is usually
5–9 MF/10 HPF, but occasionally 10–20 MF/10 HPF has
been reported [12]. The microscopic examination of 
this patient revealed the mitotic figure as 12 MF/10 HPF.
The clinical behavior of such a mitotically active tumor is
benign, and no local recurrence or metastasis is noted
during follow-up, even after myomectomy [12,13]. The
underlying etiology of the higher mitotic activity in mito-
tically active leiomyoma is uncertain, however, hormonal
stimulation, both endogeneous and exogeneous, may
play a role in the increased number of mitotic figures in
mitotically active leiomyoma.
In premenopausal women, higher mitotic index
was noted in the leiomyoma specimens of women in
the secretory phase or in women taking oral contracep-
tive pills, either combined or progestin only [10,12].
After menopause, the cessation of ovulation and the
absence of secretion of endogeneous hormone would
result in a lower rate of mitosis in the leiomyoma [12].
From a review of the literature, there were two studies
that investigated the relationship between tamoxifen
therapy and the change in uterine leiomyomas in post-
menopausal breast cancer patients [7,9]: the leiomyo-
ma underwent cystic and edematous changes, and the
uterus became enlarged and fragile, accompanying
atrophic endometrium. No increased mitotic figures 
in the leiomyoma was reported after tamoxifen treat-
ment. To the best of our knowledege, our report might
be the first to describe mitotically active leiomyoma in
a postmenopausal breast cancer patient undergoing
tamoxifen therapy.
In conclusion, we believe that endometrial prolifer-
ation and mitotically active leiomyoma of the uterus
may be related to tamoxifen therapy. In addition to the
endometrial changes, we should not neglect mitotically
active leiomyoma of the uterus in breast cancer patients
undergoing tamoxifen therapy.
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